CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
CRBPCorbus Pharmaceuticals(CRBP) Newsfilter·2024-01-26 20:30

CRB-701临床试验结果 - CRB-701 (SYS6002)的Q3W进度表显示，在预测的治疗相关剂量下，ORR为43%，DCR为71%[1] - CRB-701在临床试验中表现出良好的耐受性，大多数不良事件为一级或二级，并可逆转，未观察到三级以上的不良事件[2] - CRB-701 (SYS6002)的PK数据显示，TAb、ADC和MMAE的浓度与剂量成正比，与EV相比，CRB-701的游离MMAE浓度较低[3]